Clinical Trial Detail

NCT ID NCT02755272
Title A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Fox Chase Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab

Carboplatin + Gemcitabine

Age Groups: adult

No variant requirements are available.